Zacks Investment Research on MSN2d
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...
Novo Nordisk to pay $2 billion for new weight loss drug
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...
pharmaphorum3d
Novo Nordisk closes on EU okay for haemophilia antibody
Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...
Fierce Biotech2d
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...
Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug
Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...
Fox Business16d
Novo Nordisk shares fall on weight-loss drug trial
Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...